Blurbs

Autolus Therapeutics (AUTL) Receives a Buy from Mizuho Securities

Mizuho Securities analyst Mara Goldstein maintained a Buy rating on Autolus Therapeutics (AUTLResearch Report) today and set a price target of $18.00. The company’s shares closed last Monday at $2.32, close to its 52-week low of $2.20.

According to TipRanks.com, Goldstein is a 1-star analyst with an average return of -0.8% and a 33.4% success rate. Goldstein covers the Healthcare sector, focusing on stocks such as Adaptimmune Therapeutics, Iovance Biotherapeutics, and Neoleukin Therapeutics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Autolus Therapeutics with a $14.00 average price target.

See the top stocks recommended by analysts >>

Autolus Therapeutics’ market cap is currently $232.7M and has a P/E ratio of -1.42.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Autolus Therapeutics Plc is a biopharmaceutical company. It engages in the development of cancer treatments. The firm’s portfolio includes B Cell Malignancies, Multiple Myeloma, T Cell Lymphoma, GD2+ Tumors, and Prostate Cancer. The company was founded by Martin Pulé in February 2018 and is headquartered in London, the United Kingdom.

Read More on AUTL:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos